Browse studies

Find your next paid study

27,270 recruiting studies available now

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 48-week SAR448851 Treatment Followed by Open-label Extension in Participants With Early Alzheimer's Disease

This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The pur…

Dementia, Alzheimer's TypeAlzheimer's Disease

Estimated

~$75 – $3,000

Actual pay is set by the research site.

SanofiNCT07688213

Phase 1

Characterizing the Brain Circuitry and Neural Activity Mediating Frustration

Background: Irritability can be defined as an unusually strong response to frustration; these responses may include severe temper outbursts and a constant gru…

Irritability

Estimated

~$500 – $6,750

Actual pay is set by the research site.

National Institute of Mental Health (NIMH)NCT06484088

Pharmacogenomic Test Assessment for Medication Management in the Advancement of Medicine

Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.

Pharmacogenomic Testing for Medication Management

Estimated

~$10 – $1,050

Actual pay is set by the research site.

ClinLogic LLCNCT02738047

Observational

A Prospective, Double-Arm, Randomized Controlled Trial Evaluating the Barrier Function, Regenerative Capacity, and Soft Tissue Outcomes of Acellular Dermal Matrix Compared to Resorbable Collagen Membranes in Edentulous Ridge Augmentation

This investigator-initiated study will compare ADM and resorbable cross-linked collagen membrane barriers for guided bone regeneration at atrophic lateral ridg…

Acellular Dermal MatrixBone GraftingSoft Tissue Grafting

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Alabama at BirminghamNCT07613047

Tornier Perform™ Reversed Monopost Study

This study is a Multi-center, Prospective Follow-up, Non-significant risk, Post-Market Clinical Follow-Up (PMCF) study to Evaluate the Safety and Effectiveness…

Non-inflammatory Degenerative Joint DiseaseRhematoid ArthritisCorrection of Functional Deformity+3 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Stryker Trauma and ExtremitiesNCT07764614

Phase 3

A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin an…

Advanced Endometrial CarcinomaRecurrent Endometrial Carcinoma

Estimated

~$50 – $1,350

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07198074

Phase 1

An Open-label, Multi-center, First in Human Phase I Global Dose Escalation and Expansion Study of INR731 Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer

The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of IN…

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT07570979

Phase 3

A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) in Adult Patients With Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic Therapy

The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether speso…

Pyoderma Gangrenosum

Estimated

~$50 – $2,100

Actual pay is set by the research site.

LEO PharmaNCT06624670

Phase 2

A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) …

Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Bristol-Myers SquibbNCT07063745

A Long-term Multicenter Prospective Observational Study Evaluating the Comparative Effectiveness and Safety of Sarepta Gene Transfer Therapy vs. Standard of Care in Participants With Duchenne Muscular Dystrophy Under Conditions of Routine Clinical Practice

This is a multicenter, prospective, observational Phase 4 study including a post marketing safety requirement, designed to collect both medical history data an…

Duchenne Muscular Dystrophy

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Sarepta Therapeutics, Inc.NCT06270719

Phase 1

A Phase 1 Open-Label Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike, A Next-Generation SARS-CoV-2 Booster Vaccine Via Intranasal and Inhalational Routes, in Previously Vaccinated Adults

This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spik…

COVID-19

Estimated

~$500 – $6,750

Actual pay is set by the research site.

National Institute of Allergy and Infectious Diseases (NIAID)NCT07536308

Phase 3

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in partici…

Non-small Cell Lung Cancer

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Bristol-Myers SquibbNCT06561386